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Abstract
Purpose: Because in vitro studies suggest that low levels of electromagnetic fields may modify cancer cell
growth, we hypothesized that systemic delivery of a combination of tumor-specific frequencies may have
a therapeutic effect. We undertook this study to identify tumor-specific frequencies and test the feasibility
of administering such frequencies to patients with advanced cancer.
Patients and methods: We examined patients with various types of cancer using a noninvasive
biofeedback method to identify tumor-specific frequencies. We offered compassionate treatment to some
patients with advanced cancer and limited therapeutic options.
Results: We examined a total of 163 patients with a diagnosis of cancer and identified a total of 1524
frequencies ranging from 0.1 Hz to 114 kHz. Most frequencies (57–92%) were specific for a single tumor
type. Compassionate treatment with tumor-specific frequencies was offered to 28 patients. Three patients
experienced grade 1 fatigue during or immediately after treatment. There were no NCI grade 2, 3 or 4
toxicities. Thirteen patients were evaluable for response. One patient with hormone-refractory breast
cancer metastatic to the adrenal gland and bones had a complete response lasting 11 months. One patient
with hormone-refractory breast cancer metastatic to liver and bones had a partial response lasting 13.5
months. Four patients had stable disease lasting for +34.1 months (thyroid cancer metastatic to lung), 5.1
months (non-small cell lung cancer), 4.1 months (pancreatic cancer metastatic to liver) and 4.0 months
(leiomyosarcoma metastatic to liver).
Conclusion: Cancer-related frequencies appear to be tumor-specific and treatment with tumor-specific
frequencies is feasible, well tolerated and may have biological efficacy in patients with advanced cancer.
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Background
We have previously shown that the intrabuccal adminis-
tration of low and safe levels of electromagnetic fields,
amplitude-modulated at a frequency of 42.7 Hz by means
of a battery-powered portable device modifies the electro-
encephalographic activity of healthy subjects [1,2], and is
associated with subjective and objective relaxation effects
[3]. We have also shown that sequential administration of
four insomnia-specific frequencies, including 42.7 Hz,
results in a significant decrease in sleep latency and a sig-
nificant increase in total sleep time in patients suffering
from chronic insomnia [4,5]. This approach has been
termed Low Energy Emission Therapy (LEET)[4]. Dosi-
metric studies have shown that the amount of electromag-
netic fields delivered to the brain with this approach is
100 to 1000 times lower than the amount of electromag-
netic fields delivered by handheld cellular phones and
does not result in any heating effect within the brain [6].
The U.S. FDA has determined that such a device is not a
significant risk device. A long-term follow-up survey of
807 patients who have received this therapy in the U.S.,
Europe and Asia revealed that the rate of adverse reactions
were low and were not associated with increases in the
incidence of malignancy or coronary heart disease [7].
While many discoveries in medicine have evolved from a
scientific rationale based on in vitro and in vivo findings,
several seminal discoveries are the results of biological
effects first observed in humans. For example, the devel-
opment of modern cancer chemotherapy can be traced
directly to the clinical observation that individuals
exposed to mustard gas, a chemical warfare agent, had
profound lymphoid and myeloid suppression. These
observations led Goodman and Gilman to use this agent
to treat cancer[8]. Given the advantageous safety profile of
athermal, non-ionizing radiofrequency electromagnetic
fields[7] and the emerging evidence that low levels of elec-
tromagnetic or electric fields may modify the growth of
tumor cells [9-11], we hypothesized that the growth of
human tumors might be sensitive to different but specific
modulation frequencies. We tested this hypothesis
through examination of a large number of patients with
biopsy-proven cancer. Using a patient-based biofeedback
approach we identified strikingly similar frequencies
among patients with the same type of cancer and observed
that patients with a different type of cancer had biofeed-
back responses to different frequencies. These findings
provided strong support for our initial hypothesis. Fol-
lowing identification of tumor-specific frequencies in 163
patients with a diagnosis of cancer, we offered compas-
sionate treatment to 28 patients with advanced cancer and
limited palliative therapeutic options. We are reporting
the results of our frequency discovery studies as well as the
results of a feasibility study making use of Low Energy
Emission Therapy in the treatment of cancer.
Methods
Frequency discovery consists in the measurement of vari-
ations in skin electrical resistance, pulse amplitude and
blood pressure. These measurements are conducted while
individuals are exposed to low and safe levels of ampli-
tude-modulated frequencies emitted by handheld devices.
Exposure to these frequencies results in minimal absorp-
tion by the human body, which is well below interna-
tional electromagnetic safety limits [12,13]. Patients are
lying on their back and are exposed to modulation fre-
quencies generated by a frequency synthesizer as
described below. Variations in the amplitude of the radial
pulse were used as the primary method for frequency
detection. They were defined as an increase in the ampli-
tude of the pulse for one or more beats during scanning of
frequencies from 0.1 to 114,000 Hz using increments of
100 Hz. Whenever a change in the amplitude of the pulse
is observed, scanning is repeated using increasingly
smaller steps, down to 10-3 Hz. Frequencies eliciting the
best biofeedback responses, defined by the magnitude of
increased amplitude and/or the number of beats with
increased amplitude, were selected as tumor-specific fre-
quencies.
During our initial search for frequencies in patients with a
diagnosis of cancer, we identified frequencies in the 1,000
to 15,000 Hz range. The range of these frequencies was
higher than the frequencies previously identified in
patients with insomnia (< 300 Hz). To enable the admin-
istration of well defined signals at these higher frequen-
cies, the signal synthesizer used in the insomnia studies
was redesigned and its accuracy verified at the laboratories
of the Foundation for Research on Information Technol-
ogy in Society (IT'IS, Zurich, Switzerland). The Direct Dig-
ital Synthesis (DDS) based synthesizer AD9835 (Analog
Devices, Norwood, MA) with a frequency precision of 10-
7 was used for frequency detection in patients with a diag-
nosis of cancer. Subsequently, the same frequency synthe-
sizer was used for treatment administration. The concept
of this novel device is depicted in Figure 1.
Generation of amplitude-modulated electromagnetic
fields: the device consists of a battery-driven radiofre-
quency (RF) electromagnetic field generator connected to
a 1.5 meter long 50 Ohm coaxial cable, to the other end
of which a spoon-shaped mouthpiece made of steel is
connected with the inner conductor. The RF source of the
device corresponds to a high-level amplitude-modulated
class C amplifier operating at 27.12 MHz. The modula-
tion frequency can be varied between 0.01 Hz and 150
kHz with a modulation depth of 85 ± 5%. The output sig-
nal is controlled by a microcontroller AT89S8252 (Atmel,
Fribourg, Switzerland), i.e. duration of a session,
sequence of modulation frequencies, and duration of
each sequence are programmed prior to the treatmentJournal of Experimental & Clinical Cancer Research 2009, 28:51 http://www.jeccr.com/content/28/1/51
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with a PC connected to the panel of the device. The RF
output is adjusted to 100 mW into a 50 Ohm load using
a sinusoidal modulated test signal, which results in an
emitting power identical to that of the device used in the
treatment of insomnia [4,5].
Compassionate treatment
Following a period of search and discovery of novel
tumor-specific frequencies, outpatient treatment of
patients with advanced cancer was initiated in Switzerland
and Brazil on a compassionate basis, free of charge.
Patients self-administered treatment for 60 min, three
times a day. Oral informed consent was provided by seven
patients. All other patients signed a written informed con-
sent approved by a local human subject committee in
compliance with the Helsinki declaration and the proto-
col was registered, clinicaltrials.gov identifier #
NCT00805337. All patients had histologically confirmed
diagnosis of cancer. Except for patients with a diagnosis of
ovarian cancer, measurable disease was required. For
patients with ovarian cancer, CA 125 level was used as a
surrogate marker of measurable disease and a 50%
increase in baseline level considered evidence of disease
progression. All anticancer therapies had to be discontin-
ued for at least one month prior to treatment initiation.
Other eligibility criteria included an Eastern Cooperative
Group performance status (PS) of 0 to 2 and an estimated
life expectancy of at least 3 months.
Disease assessment
Objective response in patients with measurable disease
was assessed using the Response Evaluation Criteria in
Solid Tumors group classification [14]. Two of us (B.B.
and R.F.M.) independently reviewed all imaging studies.
Toxicity assessment
Patients were evaluated for treatment-related toxicity at a
minimum every two months as per the National Cancer
Institute Common Toxicity Criteria version 2.0. The worst
grade of toxicity per patient was recorded.
Results
Patients characteristics
A total of 115 patients were examined in Switzerland, 48
in Brazil (Table 1). There were 76 females and 87 males.
The median age was 59 years (range 19 – 84). The most
common tumor types were hepatocellular carcinoma
(46), breast cancer (32), colorectal cancer (19), and pros-
tate cancer (17).
Compassionate treatment with tumor-specific frequencies
was offered to 28 patients (Table 2). Twenty six patients
were treated in Switzerland and two patients were treated
in Brazil. All patients were white, and 63% (n = 17) were
female. Patients ranged in age from 30 to 82 years
(median, 61 years) and 75% (n = 21) had PS of 1 (vs 0 or
2). Seventy-nine percent (n = 22) of patients had received
Block diagram of the novel emitting device making use of the Direct Digital Synthesis (DDS) technology http://www.ana- log.com/library/analogdialogue/archives/38-08/dds.html Figure 1
Block diagram of the novel emitting device making use of the Direct Digital Synthesis (DDS) technology http://www.ana-
log.com/library/analogdialogue/archives/38-08/dds.html. This applicator was used for both the detection and adminis-
tration of amplitude-modulated electromagnetic frequencies. RF: radiofrequency.Journal of Experimental & Clinical Cancer Research 2009, 28:51 http://www.jeccr.com/content/28/1/51
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at least one prior systemic therapy, 57% (n = 17) had
received at least two prior systemic therapies (Table 2).
Once disease progression was observed, most patients
elected to resume or initiate chemotherapy and/or tar-
geted therapy. Seven (25%) patients requested to con-
tinue experimental treatment in combination with
chemotherapy. Continuation of experimental treatment
was allowed if desired by the patient and approved by the
patient's oncologist.
Discovery of tumor-specific frequencies
The exact duration of each examination was not recorded
but lasted on average three hours. Each patient was exam-
ined an average of 3.3 ± 3.4 times (range 1 – 26). Fre-
quency discovery was performed in patients with disease
progression, stable disease or partial response. In general,
we found more frequencies in patients with evidence of
disease progression and large tumor bulk than in patients
with stable disease, small tumor bulk or evidence of
response. When we restrict the analysis of patients exam-
ined in 2006 and 2007, i.e. at a time when we had gath-
ered more than 80% of the common tumor frequencies,
we found that patients with evidence of disease progres-
sion had positive biofeedback responses to 70% or more
of the frequencies previously discovered in patients with
the same disease. Conversely, patients with evidence of
response to their current therapy had biofeedback
responses to 20% or less of the frequencies previously dis-
covered in patients with the same disease. We also
observed that patients examined on repeated occasions
developed biofeedback responses to an increasing
number of tumor-specific frequencies over time whenever
there was evidence of disease progression. Whenever fea-
sible, all frequencies were individually retested at each fre-
quency detection session. These findings suggest that a
larger number of frequencies are identified at the time of
disease progression.
A total of 1524 frequencies ranging from 0.1 to 114 kHz
were identified during a total of 467 frequency detection
sessions (Table 1). The number of frequencies identified
in each tumor type ranges from two for thymoma to 278
for ovarian cancer. Overall, 1183 (77.6%) of these fre-
quencies were tumor-specific, i.e. they were only identi-
fied in patients with the same tumor type. The proportion
of tumor-specific frequencies ranged from 56.7% for neu-
roendocrine tumors to 91.7% for renal cell cancer. A total
of 341 (22.4%) frequencies were common to at least two
different tumor types. The number of frequencies identi-
fied was not proportional to either the total number of
patients studied or the number of frequency detection ses-
sions (Table 1).
Treatment with tumor-specific amplitude-modulated 
electromagnetic fields
Twenty eight patients received a total of 278.4 months of
experimental treatment. Median treatment duration was
Table 1: Frequency discovery in 163 patients with a diagnosis of cancer
Tumor type Number of 
patients
Number of 
frequency 
detection sessions
Number of 
frequencies
Tumor-specific 
frequencies
Nb and (%)
Frequencies 
common to two or 
more tumor types
Brain tumors 8 22 57 41 (71.9) 16
Hematologic 
malignancies
7 13 56 44 (78.6) 12
Colorectal cancer 19 40 99 67 (67.7) 32
Hepatocellular 
carcinoma
46 63 170 144 (84.7) 26
Pancreatic cancer 6 44 162 125 (77.2) 37
Ovarian cancer 10 66 278 219 (78.8) 59
Breast cancer 32 93 188 141 (75.0) 47
Prostate cancer 17 80 187 150 (80.2) 37
Lung cancer 6 17 80 57 (71.3) 23
Renal cell cancer 2 3 36 33 (91.7) 3
Thyroid cancer 1 14 112 89 (79.5) 23
Neuroendocrine 
tumor
5 5 30 17 (56.7) 13
Bladder cancer 2 4 31 25 (80.6) 6
Leiomyosarcoma 1 2 36 31 (86.1) 5
Thymoma 112 0  N / A 2
Total 163 467 1524 1183 (77.6) 341
The following frequencies were common to most patients with a diagnosis of breast cancer, hepatocellular carcinoma, prostate cancer and 
pancreatic cancer: 1873.477 Hz, 2221.323 Hz, 6350.333 Hz and 10456.383 HzJournal of Experimental & Clinical Cancer Research 2009, 28:51 http://www.jeccr.com/content/28/1/51
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4.1 months per patient; range 1 to +50.5. Patients treated
in Switzerland were re-examined on average every other
month for frequency detection; patients treated in Brazil
were only examined once. Novel frequencies discovered
upon re-examination were added to the treatment pro-
gram of patients receiving experimental treatment. The
first treatment programs consisted of combinations of less
than ten frequencies while the most recent treatment pro-
grams exceed 280 frequencies (Figure 2).
The evolution of treatment programs through incremental
addition of tumor-specific frequencies is illustrated by the
case of a 51 year old woman with ovarian cancer. This
patient was diagnosed with FIGO stage III (G2–G3) ovar-
ian cancer in October 1997 and had received multiple
courses of palliative chemotherapy until 2005. As seen on
Figure 2, the initial treatment consisting of 15 frequencies
did not yield any response. Upon re-examination, 11
additional frequencies (total of 26) were added to the
treatment program in August 05. Because of disease pro-
gression, treatment with single agent bevacizumab was
initiated in November 05. Interestingly, the CA 125 level
had decreased by 200 units between October and Novem-
ber 2005, prior to the initiation of bevacizumab. Com-
bined treatment with amplitude-modulated
electromagnetic fields and bevacizumab resulted in a
decrease in CA 125 level from 2140 to 540 in May 06.
Treatment was supplemented with cyclophosphamide
from March to September 07. The patient was hospital-
ized with pneumonia and elected to only receive ampli-
tude-modulated electromagnetic fields since September
07. As of April 1, 2009 the patient has stable disease and
is asymptomatic. She has been receiving experimental
treatment without interruption for a total of +50.5
months.
This case provides empirical evidence that adding tumor-
specific frequencies may yield disease stabilization in
patients with evidence of disease progression. However,
addition of frequencies over time does not appear to be a
requirement for therapeutic efficacy. This is illustrated by
the case of a 59 yo postmenopausal female with ER/PR
positive, ERBB2 negative breast cancer with biopsy con-
firmed metastasis to the left ischium and right adrenal
gland (Figure 3A, Figure 3C, Figure 3D). She had been pre-
viously treated with radiation therapy to the left ischium,
had received five different hormonal manipulations
(tamoxifen, anastrozole, exemestane, fulvestran and meg-
estrol). She had also received capecitabine, which had
been discontinued because of gastrointestinal side effects.
The patient was examined only once. In June 2006, at the
time of treatment initiation, the patient complained of
severe left hip pain, which was limiting her mobility
despite the intake of opioids. Within two weeks of exper-
imental treatment initiation with breast cancer-specific
frequencies, the patient reported complete disappearance
of her pain and discontinued the use of pain medications.
She also reported a significant improvement in her overall
condition. As seen on Figure 3B and 3E, PET-CT obtained
three months after treatment initiation showed complete
disappearance of the right adrenal and left ischium
lesions. The complete response lasted 11 months. Intrigu-
ingly, the patient had developed intermittent vaginal
spotting in the months preceding experimental treatment
initiation. A minimally enhancing uterine lesion was
observed on PET-CT prior to treatment initiation. Upon
follow-up, FDG uptake increased significantly (Figure 3B)
and the patient was diagnosed with uterine cancer by hys-
teroscopy. The patient underwent hysterectomy, which
revealed endometrial adenocarcinoma. Hence, while
treatment with breast cancer specific frequencies resulted
in a complete response, it did not affect the growth of
endometrial adenocarcinoma. This observation suggests
that breast cancer frequencies are tumor-specific as a
response of the metastatic breast cancer was observed
while a uterine tumor progressed.
Table 2: Characteristics of patients treated with amplitude-
modulated electromagnetic fields
Characteristic No %
Age, years
Median 61.0
Range 30–82
Sex
Male 11 39.3
Female 17 60.7
Performance status, ECOG
01 3 . 6
12 1 7 5 . 0
26 2 1 . 4
Sites of primary disease
Breast 7 25.0
Ovary 5 17.9
Pancreas 3 10.7
Colon 2 7.1
Prostate 2 7.1
Glioblastoma multiforme 1 3.6
Hepatocellular carcinoma 1 3.6
Mesothelioma 1 3.6
Neuroendocrine 1 3.6
NSCLC 1 3.6
Oligodendroglioma 1 3.6
SCLC 1 3.6
Sarcoma 1 3.6
Thyroid 1 3.6
Prior systemic therapy
Yes 22 78.6
No 6 21.4Journal of Experimental & Clinical Cancer Research 2009, 28:51 http://www.jeccr.com/content/28/1/51
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As seen in Table 3, sixteen patients were evaluable for
response by RECIST criteria. A complete response was
observed in a patient with hormone-refractory breast can-
cer metastatic to the adrenal gland and bone (Figure 3),
which lasted 11 months. A partial response was observed
in a patient with hormone-refractory breast cancer meta-
static to bone and liver, which lasted 13.5 months. Five
patients had stable disease for +34.1 months (thyroid can-
cer with biopsy-proven lung metastases), 6.0 months
(mesothelioma metastatic to the abdomen), 5.1 months
(non-small cell lung cancer), and 4.1 months (pancreatic
cancer with biopsy-proven liver metastases). As of April 1,
2009 two patients are still receiving experimental treat-
ment and four patients are alive.
Adverse and beneficial reactions
No patients receiving experimental therapy reported any
side effect of significance and no patient discontinued
treatment because of adverse effects. Three patients
(10.7%) reported grade I fatigue after receiving treatment.
One patient (3.6%) reported grade I mucositis after long-
term use (26 months) of the experimental device and con-
comitant chemotherapy. Two patients with severe bony
pain prior to initiation of experimental treatment
reported significant symptomatic improvement. Both
patients had breast cancer metastatic to the skeleton.
Discussion
In this report we describe the discovery of tumor-specific
amplitude modulation frequencies in patients with a
diagnosis of cancer using noninvasive biodfeedback
methods. Our approach represents a significant departure
Compassionate treatment of a 51 year old patient with ovarian cancer FIGO IIIC with extensive peritoneal carcinomatosis  since October 1997 Figure 2
Compassionate treatment of a 51 year old patient with ovarian cancer FIGO IIIC with extensive peritoneal 
carcinomatosis since October 1997. The patient received paclitaxel and cisplatin from March 97, then docetaxel and car-
boplatin, doxorubicin, and gemcitabine. Because of progression of disease the patient was offered compassionate treatment 
with amplitude-modulated electromagnetic fields as of May 05. As seen below, the initial treatment consisting of 15 frequencies 
(May 05) did not yield any response. Upon re examination, 11 additional frequencies (26) were added to the treatment pro-
gram in August 05. Because of disease progression, treatment with single agent bevacizumab was initiated in November 05. 
Interestingly, the CA 125 level had decreased by 200 units prior to the initiation of bevacizumab. Combined treatment with 
amplitude-modulated electromagnetic fields and bevacizumab resulted in a decrease in CA 125 level from 2140 to 540 in May 
06. Treatment was supplemented with cyclophosphamide from March to September 07. The patient was hospitalized with 
pneumonia and elected to only receive amplitude-modulated electromagnetic fields since September 07. As of April 09, i.e. 
50.5 months after treatment initiation the patient has stable disease and is asymptomatic. The numbers above the arrows rep-
resent the total number of cancer-specific frequencies included in the treatment program.
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59 yo postmenopausal female with ER/PR positive, ERBB2 negative breast cancer with biopsy confirmed metastasis to the left  ischium and right adrenal gland Figure 3
59 yo postmenopausal female with ER/PR positive, ERBB2 negative breast cancer with biopsy confirmed 
metastasis to the left ischium and right adrenal gland. A) Baseline PET MIP image demonstrates metastatic disease of 
the right adrenal gland (small arrow) and the left ischium (large arrow). B) PET MIP image four months after baseline shows the 
FDG activity in the right adrenal and left ischium has resolved indicating response to therapy. However, a primary uterine 
tumor, which was barely detectable in the baseline study, grew during the same time frame (arrow). C) Baseline PET/CT (left 
panel): The non-contrast CT shows an enlarged right adrenal gland. D) Baseline PET/CT (right panel): The fused PET/CT dem-
onstrates increased FDG activity in the enlarged right adrenal gland. E) Follow-up PET/CT: The fused PET/CT four months 
after baseline shows a decrease in FDG activity of the right adrenal gland. Note the corresponding decrease in size also.
A B
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from the development of novel forms of chemotherapy
and targeted therapy, which commonly rely on in vitro
and animal experiments, followed by phase I studies to
assess tolerability. Given the absence of theoretical health
risks related to the administration of very low level of elec-
tromagnetic fields and the excellent safety profile
observed in patients suffering from insomnia treated for
up to several years [7], our approach was entirely patient-
based. This allowed us to examine a large number of
patients with tumor types commonly encountered in
Switzerland and Brazil. It also allowed us to examine the
same patients on multiple occasions, which decreased the
variability inherent to a single frequency detection ses-
sion.
Examination of patients with cancer led to the identifica-
tion of frequencies that were either specific for a given
tumor type or common to two or more tumor types. We
observed that most frequencies were tumor-specific.
Indeed, when the analysis of frequencies is restricted to
tumor types analyzed following a minimum of 60 fre-
quency detection sessions (breast cancer, hepatocellular
carcinoma, ovarian cancer and prostate cancer), at least
75% of frequencies appear to be tumor-specific. Some fre-
quencies such as 1873.477 Hz, 2221.323 Hz, 6350.333
Hz and 10456.383 Hz are common to the majority of
patients with a diagnosis of breast cancer, hepatocellular
carcinoma, prostate cancer and pancreatic cancer. The
small number of frequency detection sessions conducted
in patients with thymoma, leiomyosarcoma, and bladder
cancer constitutes a limitation of our study and an accu-
rate estimate of tumor-specific versus nonspecific frequen-
cies cannot yet be provided for these tumor types. Only
one patient with thyroid cancer metastatic to the lung was
examined 14 times over the course of the past three years
and this led to the discovery of 112 frequencies, 79.5% of
which were thyroid cancer-specific. These combined find-
ings strongly suggest that many tumor types have a pro-
portion of tumor-specific frequencies of more than 55%.
The high number of frequencies observed in patients with
ovarian cancer may be due to the various histologies asso-
ciated with this tumor type.
We observed excellent compliance with this novel treat-
ment as patients were willing to self-administer experi-
mental treatment several times a day. The only observed
adverse effects in patients treated with tumor-specific fre-
quencies were grade I fatigue after treatment (10.6%) and
grade I mucositis (3.6%). Fatigue was short-lived and no
patient reported persistent somnolence. Of note, mucosi-
tis only occurred concomitantly with the administration
of chemotherapy. The frequency and severity of adverse
effects is analogous to what was observed in patients
treated with insomnia-specific frequencies [5] and con-
firm the feasibility of this therapeutic approach and its
excellent tolerability.
We did not observe any untoward reaction in patient
receiving either chemotherapy or targeted therapy in com-
bination with amplitude-modulated electromagnetic
fields. While these latter findings are limited to 7 patients,
they are consistent with the lack of theoretical interaction
between very low level of electromagnetic fields and anti-
cancer therapy. Furthermore, one patient received pallia-
tive radiation therapy concomitantly with experimental
therapy without any adverse effects. These findings pro-
vide preliminary data suggesting that amplitude-modu-
lated electromagnetic fields may be added to existing
anticancer therapeutic regimens.
The objective responses observed suggest that electromag-
netic fields amplitude-modulated at tumor-specific fre-
quencies may have a therapeutic effect. Of the seven
patients with metastatic breast cancer, one had a complete
response lasting 11 months, another one a partial
response lasting 13.5 months. These data provide a strong
rationale to further study this novel therapy in breast can-
cer. The increased knowledge of tumor-specific frequen-
cies and the preliminary evidence that additional tumor-
specific frequencies may yield a therapeutic benefit (Fig-
ure 2) provides a strong rationale for the novel concept
that administration of a large number of tumor-specific
frequencies obtained through the follow-up of numerous
patients may result in long-term disease control. This
hypothesis is partially supported by two long-term survi-
Table 3: Independent review of best response (N = 16) according 
to RECIST criteria
Best response No %
Complete response* 1 3.6
Partial response** 1 3.6
Stable disease*** 5 28.6
Progressive disease**** 9 21.4
Not available for response assessment 12 60.7
* Duration of the complete response was 11 months (breast cancer 
metastatic to bone and adrenal gland)
** Duration of the partial response was 13.5 months (breast cancer 
metastatic to bone and liver)
*** Duration of stable disease was +34.1 months (thyroid cancer 
metastatic to lung), 6.0 months (mesothelioma metastatic to 
abdomen), 5.1 months (Non-small cell lung cancer), 4.1 months 
(pancreatic cancer metastatic to liver), and 4.0 months 
(leiomyosarcoma metastatic to liver).
**** One patient with ovarian cancer had progressive disease while 
receiving 26 frequencies. She has now stable disease and has been 
receiving amplitude-modulated electromagnetic fields for +50.5 
months (Figure 2).
Not included is a patient with breast cancer metastatic to bone and 
liver with a near complete response who started systemic 
chemotherapy with docetaxel and bevacizumab within 4 weeks of 
experimental treatment initiation.Journal of Experimental & Clinical Cancer Research 2009, 28:51 http://www.jeccr.com/content/28/1/51
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vors reported in this study, a patient with thyroid cancer
metastatic to the lung with stable disease for +34.1
months and a heavily pretreated patient with ovarian car-
cinoma and peritoneal carcinomatosis with stable disease
for +50.5 months. Additional support for this hypothesis
stems from the observation that four patients with
advanced hepatocellular carcinoma in a follow-up phase
II study by Costa et al had a partial response, two of them
lasting more than 35 months[15]. These exciting results
provide hope that this novel therapeutic approach may
yield long-term disease control of advanced cancer.
Kirson et al have recently reported the use of continuous
wave (CW) electric fields between 100 KHz to 1 MHz
[10,11]. These fields were CW, applied at relative high
field strengths but lower frequencies than the fields used
in our study. These frequencies were found to be effective
when applied by insulating external electrodes to animal
cancer models and patients with recurrent glioblastoma.
In contrast to our approach, the electric fields applied to
cancer cells and patients did not include any amplitude
modulation. Hence, it is likely that these two different
therapeutic modalities have different mechanisms of
action.
Computer simulation studies have shown that the specific
absorption rate (SAR) in the head resulting from the use
of intrabuccally-administered amplitude-modulated elec-
tromagnetic fields is in the range of 0.1–100 mW/kg[1].
Hence, the SAR outside the head is substantially below 0.1
mW/kg. We had previously hypothesized that the mecha-
nism of action of electromagnetic fields amplitude-mod-
ulated at insomnia-specific frequencies was due to
modification in ions and neurotransmitters[6], as demon-
strated in animal models[16], as such biological effects
had been reported at comparable SARs. However, this
hypothesis does not provide a satisfactory explanation for
the clinical results observed in patients with advanced
cancer. First, the levels of electromagnetic fields delivered
to organs such as the liver, adrenal gland, prostate and hip
bones, are substantially lower than the levels delivered to
the head. Second, there is currently no acceptable ration-
ale for a systemic anti-tumor effect that would involve
subtle changes in neurotransmitters and ions within the
central nervous system. Consequently, we hypothesize
that the systemic changes (pulse amplitude, blood pres-
sure, skin resistivity) observed while patients are exposed
to tumor-specific frequencies are the reflection of a sys-
temic effect generated by these frequencies. These observa-
tions suggest that electromagnetic fields, which are
amplitude-modulated at tumor-specific frequencies, do
not act solely on tumors but may have wide-ranging
effects on tumor host interactions, e.g. immune modula-
tion. The exciting results from this study provide a strong
rationale to study the mechanism of action of tumor-spe-
cific frequencies in vitro and in animal models, which may
lead to the discovery of novel pathways controlling cancer
growth.
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